TICKERNERD
Menu
EOLSEOLSHealthcare · Drug Manufacturers - Specialty & Generic

EOLS Stock Forecast: Evolus, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$8.39
+0.48% on the day

The 7 Wall Street analysts covering Evolus, Inc. hold a median 12-month price target of $14 — +66.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 87 of 100 as at 21 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$551.5M
Ticker Nerd rank
87 / 100
Median analyst target
$14
Analysts covering
7
Total return, dividends reinvested
1W
+2.9%
1M
+44.5%
YTD
+26.2%
1Y
+13.0%
From 52W high
−2.4%
From 52W low
+112.9%
$3.94
$8.60
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

EOLS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Evolus, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Aug 2026
87 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
94
Quality
92
Growth
90
Revisions
83
Volatility
66
Size
53
Momentum
44
Accruals
41
Issuance
26

Value (94): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (26): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

EOLS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on EOLS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5.00$10.00$15.00$20.00Oct 25Jan 26Apr 26Jul 26EOLSHigh $20Median $14Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says7 analysts
6 Buy1 Hold0 Sell
Low $12Median $14High $20

The green dot is the last close — the median target sits +66.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 June 2026BTIGReiteratesBuy$13
4 Mar 2026BTIGReiteratesBuy—
3 Feb 2026HC Wainwright & Co.MaintainsBuy—
22 Jan 2026BTIGMaintainsBuy—
13 Jan 2026StifelMaintainsBuy—
9 Jan 2026HC Wainwright & Co.ReiteratesBuy—
24 Dec 2025NeedhamReiteratesHold—
2 Dec 2025MizuhoMaintainsOutperform—
8 Sept 2025BTIGReiteratesBuy—
6 Aug 2025BTIGMaintainsBuy—
6 Aug 2025HC Wainwright & Co.MaintainsBuy—
6 Aug 2025NeedhamDowngradeHold—
8 May 2025NeedhamReiteratesBuy—
17 Apr 2025BTIGInitiatesBuy—
10 Apr 2025HC Wainwright & Co.ReiteratesBuy—
9 Apr 2025NeedhamReiteratesBuy—
5 Mar 2025BarclaysMaintainsOverweight—
5 Mar 2025HC Wainwright & Co.ReiteratesBuy—
5 Mar 2025NeedhamReiteratesBuy—
14 Feb 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EOLS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

EOLS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Evolus, Inc. (EOLS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−10.4×

Cheaper than 93% of US stocks

Price / sales
1.7×

Cheaper than 57% of US stocks

Price / book
−17.7×

Cheaper than 98% of US stocks

EV / EBITDA
−57.3×

Cheaper than 95% of US stocks

Growth & margins
Revenue growth (YoY)
21.2%

Higher than 71% of US stocks

Earnings growth (YoY)
21.2%

Higher than 60% of US stocks

Gross margin
68.0%

Higher than 81% of US stocks

Operating margin
−3.9%

Higher than 28% of US stocks

Net margin
−10.8%

Higher than 19% of US stocks

Returns & dividend
Return on equity
223.5%

Higher than 98% of US stocks

Return on assets
−5.4%

Higher than 31% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

EOLS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
EOLSEvolus, Inc.$551.5M
87
AQSTAquestive Therapeutics, Inc.$584.9M
50
KMDAKamada Ltd.$483.3M
95
CGCCanopy Growth Corp.$474.5M
48
TLRYTilray Brands, Inc.$659.2M
18
IRWDIronwood Pharmaceuticals, Inc.$699.5M
100
BIOABioAge Labs, Inc.$420.7M
41

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Evolus, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest EOLS news & analysis

Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade

Zacks Investment Research · 11 Aug 2026positive

Zacks reports that the average of Wall Street analysts' price targets for Evolus (EOLS) implies a potential upside of roughly 106%, while noting that the reliability of this metric is questionable. The article also highlights a positive trend in earnings estimate revisions, which could translate into upside for the stock.

Why it matters — EOLS watchers would care because analyst price targets and improving earnings estimate revisions are commonly watched signals for the stock's future performance.

Evolus: The Injectable Platform Is Becoming The Real Moat

Seeking Alpha · 11 Aug 2026positive

Evolus is transitioning from a single-product company to a multi-product aesthetics platform, leveraging its distribution network and loyalty ecosystem. Q2 2026 results showed 21% revenue growth and positive adjusted EBITDA, with management raising guidance and projecting 2028 revenue of $450M–$500M.

Why it matters — The article suggests Evolus is building a durable competitive advantage (a "moat") through its injectable platform, which could drive recurring revenue and operating leverage as it expands beyond its single-product focus.

Evolus, Inc. (EOLS) Q2 2026 Earnings Call Transcript

Seeking Alpha · 6 Aug 2026neutral

Evolus, Inc. (EOLS) published the transcript of its Q2 2026 earnings call on Seeking Alpha. The excerpt provided consists solely of the transcript's title, with no additional content or figures.

Why it matters — EOLS watchers would care because the earnings call transcript gives access to management's own discussion of the company's quarterly results.

Evolus, Inc. (EOLS) Reports Break-Even Earnings for Q2

Zacks Investment Research · 6 Aug 2026positive

Evolus, Inc. reported break-even quarterly earnings per share for Q2, matching the Zacks Consensus Estimate of a loss of $0.01, and improving from a loss of $0.24 per share a year earlier.

Why it matters — A break-even quarter versus the consensus loss estimate marks a notable earnings improvement for Evolus watchers.

Evolus Q2 Earnings Call Highlights

MarketBeat · 6 Aug 2026positive

Evolus reported second-quarter revenue growth of 21% and raised the lower end of its full-year 2026 revenue outlook, citing market-share gains in neurotoxins and hyaluronic acid injectable gels, continued customer adoption of its portfolio, and expanding international operations.

Why it matters — The revenue growth and raised outlook signal improving business momentum for EOLS watchers tracking the company's market expansion.

FAQ

Frequently asked questions about EOLS stock

What is the EOLS stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Evolus, Inc. have a median 12-month price target of $14, with estimates ranging from $12 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is EOLS stock a buy right now?

Of the 7 analysts covering Evolus, Inc., 6 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Evolus, Inc. 87 out of 100 across roughly 4,600 US stocks as at 21 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank EOLS?

As at 21 Aug 2026, Evolus, Inc. ranks 87 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (94 of 100).

Will EOLS stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +66.9% from the last close, and Ticker Nerd's factor model ranks Evolus, Inc. 87 out of 100 as at 21 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the EOLS stock forecast for 2030?

No analyst covering Evolus, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EOLS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $20 over the next 12 months.

How has EOLS stock performed over the past year?

Evolus, Inc. returned +13.0% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Evolus, Inc. do?

Evolus is a performance beauty company specializing in injectable aesthetic products within the global cash-pay aesthetics market across the United States, Canada, Europe, and Australia. The company's flagship product, Jeuveau, is a proprietary botulinum toxin formulation designed to temporarily improve the appearance of moderate to severe frown lines in adults.

What is the latest news on EOLS?

The most recent item we track (Zacks Investment Research, 11 Aug 2026): "Wall Street Analysts Believe Evolus (EOLS) Could Rally 106.08%: Here's is How to Trade". Zacks reports that the average of Wall Street analysts' price targets for Evolus (EOLS) implies a potential upside of roughly 106%, while noting that the reliability of this metric is questionable. The article also highlights a positive trend in earnings estimate revisions, which could translate into upside for the stock.

Company

About Evolus, Inc.

Evolus is a performance beauty company specializing in injectable aesthetic products within the global cash-pay aesthetics market across the United States, Canada, Europe, and Australia. The company's flagship product, Jeuveau, is a proprietary botulinum toxin formulation designed to temporarily improve the appearance of moderate to severe frown lines in adults. Evolysse, its complementary portfolio offering, consists of injectable hyaluronic acid gels engineered with Cold-X Technology to address dynamic facial wrinkles. Evolus operates exclusively in the self-pay aesthetic segment, enabling a customer-centric business model distinct from competitors serving reimbursed markets. The company leverages a digital-first platform and consumer loyalty program to engage younger, wellness-conscious demographics. With approximately one million enrolled consumers in its Rewards program, Evolus positions itself at the intersection of medical aesthetics and consumer beauty, targeting the rapidly expanding segment of aesthetic neurotoxins and dermal fillers within the broader global aesthetics market.

CEO Mr. David Moatazedi · 353 employees · United States · https://www.evolus.com